Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, revenue was PLN 94.76 million compared to PLN 105.1 million a year ago. Net loss was PLN 15.62 million compared to net income of PLN 0.302 million a year ago. Basic loss per share from continuing operations was PLN 0.31 compared to basic earnings per share from continuing operations of PLN 0.01 a year ago. Diluted loss per share from continuing operations was PLN 0.31 compared to diluted earnings per share from continuing operations of PLN 0.01 a year ago.